PC
FOLD

Paulson & Co’s Amicus Therapeutics FOLD Stock Holding History

Paulson & Co’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$469K Buy
+32,400
New +$464K 0.02% 9

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Paulson & Co's FOLD Position: Q1 2026 in Review

Paulson & Co opened a new position in Amicus Therapeutics (FOLD) in Q1 2026: 32,400 shares worth $469K. The stake represents 0.02% of the portfolio and ranks #9 among its holdings.

298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Paulson & Co held 32,400 shares of Amicus Therapeutics worth $469K as of Q1 2026.
  • Amicus Therapeutics was a new Paulson & Co position in Q1 2026.
  • Amicus Therapeutics made up 0.02% of Paulson & Co's portfolio in Q1 2026, its #9 holding.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Paulson & Co's 13F filing for Q1 2026, filed 15 May 2026.